Detalhe da pesquisa
1.
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
J Neurol Neurosurg Psychiatry
; 2024 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242680
2.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
J Neurol Neurosurg Psychiatry
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569872
3.
Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study.
Mult Scler
; : 13524585241245318, 2024 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38616518
4.
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
Mult Scler
; 30(6): 707-713, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456445
5.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369086
6.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068931
7.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414534
8.
External validation of a clinical prediction model in multiple sclerosis.
Mult Scler
; 29(2): 261-269, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448727
9.
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
Mult Scler
; 29(9): 1099-1106, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322880
10.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler
; 29(7): 875-883, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36851894
11.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36800908
12.
Sars-CoV2 infection in pregnant women with multiple sclerosis.
Mult Scler
; 29(9): 1090-1098, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232279
13.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692895
14.
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Neurol Sci
; 44(6): 2121-2129, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689010
15.
Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center.
Turk J Med Sci
; 53(4): 962-969, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031938
16.
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Turk J Med Sci
; 53(1): 323-332, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945929
17.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 93(12): 1330-1337, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261289
18.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler
; 28(6): 958-969, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34623947
19.
Post-COVID-19 longitudinally extensive transverse myelitis: is it a new entity?
Neurol Sci
; 43(3): 1569-1573, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34816319
20.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386427